WHANIN PHARM CO.,LTD
Financials
Valuation Metrics
WHANIN PHARM CO.,LTD's Market Cap is ₩1864B. At end of 2025 it was ₩2106B. Ranked #894 of 2,421 in KR market (top 37%), #471 of 781 on KOSPI (top 60%), #97 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 42%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 186.37B KRW | KR#894/2,421 Sec#97/231 |
| Revenue | 273.47B KRW | KR#877/2,421 Sec#43/231 |
| Net Income | 20.45B KRW | KR#695/2,421 Sec#47/231 |
| Total Assets | 478.89B KRW | KR#788/2,421 Sec#45/231 |
| Net Assets | 421.01B KRW | KR#578/2,421 Sec#34/231 |
| Employees | 653 | KR#385/2,421 Sec#33/231 |
| Value | ||
| P/E | 9.11x | KR#746/2,421 Sec#36/231 |
| P/B | 0.44x | KR#671/2,421 Sec#26/231 |
| PEG | 0.37x | KR#656/2,421 Sec#40/231 |
| P/S | 0.68x | KR#1,126/2,421 Sec#54/231 |
| EV/EBITDA | 5.59x | KR#280/2,421 Sec#5/231 |
| FCF Yield | 4.12% | KR#908/2,421 Sec#53/231 |
| Profitability | ||
| ROE | 4.86% | KR#1,116/2,421 Sec#78/231 |
| ROA | 4.27% | KR#821/2,421 Sec#64/231 |
| Op. Margin | 8.16% | KR#644/2,421 Sec#52/231 |
| Revenue Growth | 5.71% | KR#1,152/2,421 Sec#113/231 |
| Earnings Growth | 24.65% | KR#678/2,421 Sec#46/231 |
| Financial Health | ||
| Debt Ratio | 13.75% | KR#225/2,421 Sec#37/231 |
| Total Debt | 2.01B KRW | KR#1,901/2,421 Sec#185/231 |
| FCF | 7.69B KRW | KR#789/2,421 Sec#46/231 |
| Cash | 63.58B KRW | KR#644/2,421 Sec#34/231 |
| Current Ratio | 4.26x | KR#353/2,421 Sec#55/231 |
| Net Debt/EBITDA | -2.76x | KR#178/2,421 Sec#6/231 |
| Dividend | ||
| Div. Yield | 2.97% | KR#639/2,421 Sec#32/231 |
| Div. Growth | 0.00% | KR—/2,421 Sec—/231 |
| Performance | ||
| 1Y Return | -8.83% | KR#946/2,421 Sec#59/231 |
| 1M Return | 0.91% | KR#1,127/2,421 Sec#86/231 |
| From 52W High | -17.46% | KR#200/2,421 Sec#9/231 |
| 1Y MDD | -22.63% | KR#97/2,421 Sec#7/231 |
| Trading | ||
| Volume | 22,890 shares | KR#1,518/2,421 Sec#150/231 |
| Trading Value | 228.5M KRW | KR#1,221/2,421 Sec#125/231 |
| Foreign Own. | 12.77% | KR#384/2,421 Sec#27/231 |
| Per Share | ||
| EPS | 1,100 KRW | KR#686/2,421 Sec#45/231 |
| BPS | 22,635 KRW | KR#494/2,421 Sec#33/231 |
Company Info
Established in 1978 and listed on the securities market in 1996, Whanin Pharmaceutical is a pharmaceutical manufacturing and sales company specializing in psychoneurotic agents. Based on 2024 IMS DATA, it holds the leading market share in the domestic psychotherapeutic drug market. With a robust drug lineup and strong network, the company boasts significant sales strengths in the psychoneurotic field and is growing with the market due to increasing prescriptions driven by the rise in mental health-related medical institutions and patient visits.